Preparation of Monoclonal Antibodies against proamastigote Leishmania infantum strain in Iran

Nourizadeh, Ezzat

Document Type : Original Article

Author

Ezzat Nourizadeh

Department Dpartment of Microbiology, College of Science , University of Mohaghegh Ardabili, Ardabil, Iran

Abstract

Introduction: Leishmania parasitic infections are the important causes of health problems in many parts of the world, especially in developing countries. Monoclonal antibodies have been used as valuable tools for the detection, treatment and characterization of the antigenic markers of parasites. This study through applicable techniques aims to produce mAbs against Iranian type of Leishmania( L). infantum. Materials and Methods: Standard strains were cultured and their antigens were used. BALB/c mice were injected with freeze-thawed promastigote twice together with Freund adjuvant. Three days before cell-fusion, the antigen through vein was injected into the mice. Then the mice were killed. After that their spleen lymphocytes were mingled with myeloma SP2/0. In the next step, the isolation of monoclones was performed by limiting dilution method.
Results: 16 mAb against promastigote form of L.infantum parasite were obtained ,3 of which showed optical density (OD) more than 1nm, designated as 5D2 FV, 4G5 FV and 5D6 FIV. Then, anti-promastigotes L.infantum mAbs were obtained from these hybrids. These antibodies are effective in the logarithmic phase of the parasite.
Conclusion: It seams these antibodies can demonstrate reaction against Iranian strain of promastigotes L. infantum and can be employed in the diagnosis of kalazar disease

Keywords

Main Subjects

immunology & Biochemistry

References

[1]. Ayele A., Seyoum Z. Review on canine leishmaniasis, etiology, clinical sign, pathogenesis, treatment and control methods. Global Veterinaria. 2016;17(4):343–352.

[2]. Gashaw enbiyale, demeke Debalke, endris Aman, birhanu Eedmim. Review on Leishmaniasis. Journal of American Science. 2018;142: 67-73.

[3]. Zarati S, Sobhan Fayez S., Hamid Sedighian H. Production of new a nanovaccineand evaluation ofit'sEffectsonbalb/c ratswith L.major. Journal of Sabzevar University of Medical Sciences, 2015 ; 21(6) : 1182-93.

[4]. Macconkey S.E.,Lopez A.,Shaw D.,Calder J. leishmanial polyarthritis in a dog. Canine Vet J. 2002; 43: 607-60.

[5]. Gavgani AS, Mohite H, Edrissian GH, Mohebali M, Davies CR. Domestic dog ownership in Iran is a risk factor for humaninfection with Leishmania infantum. Am J Trop Med Hyg. 2002; 67(5):511-5.

[6]. Sundar S. Visceral leishmaniasis. Tropical Parasitology.2015; 5( 2): 83–85.
[7]. Mcgwire B C , a.r. Satoskar A R. Leishmaniasis: clinical syndromes and treatment. An International Journal of Medicine . 2013; 107:7–14.

[8]. Uliana S R , Trinconi C T, Coelho A C , Chemotherapy of leishmaniasis: present challenges, Parasitology. 2018; 145( 4): 464–480.

[9]. Oryan A , Akbari M. Worldwide risk factors in leishmaniasis. Asian Pacific Journal of Tropical Medicine.2016 ; 9(10): 925–932.

[10]. Hosseini SM, Hatam GR, Ardehali S. Characterization of Leishmania isolated from unhealed lesions caused by leishmanization. East Mediterr Health J. 2005;11(1-2):2403.

[11]. Control of the leishmaniases. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 2010;949:1202.

[12]. Mandira, M., Anindita, B. and Swadesh, D. Monoclonal antibody affinity purification of a 78 KDa membrane protein of Leishmania donovani of Indian origin and its role in host –parasite interaction. Indian. Academy. Science.2002; 27:665-672.

[13]. Schmitz K, Geisslinger G, Tegeder I. Monoclonal antibodies in preclinical EAE models of multiple sclerosis: A systematic review. Int J Mol Sci. 2017;18:1–18.

[14]. Tomita M, Tsumoto K: Hybridoma technologies for antibody production. Immunotherapy. 2011; 3: 3 71–380.

[15]. Abdalla H S, Eltahir A G K, Samia A O, Hamid S A. Innovative serum-free medium for in vitro cultivation of promastigote forms of Leishmania species. Parasitology International. 2008;57: 138–142. [16]. Jervis S, Chapman L. A. C. , Dwivedi S, et al.Variations in visceral leishmaniasis burden, mortality and the pathway to care within Bihar, India.Parasites & Vectors.2017; 10(1): 601.

[17]. Fadili K, Messier N, Leprohon P. Role of the ABC transporter MRPA (PGPA) in antimony resistance in leishmania infantum axenic and intracellular amastigotes. Antimicrob Agents Chemoter. 2005; 49 (5):1988-1993. [18].

[18]. Tavaresa J b, Ouaissic A. , P.K.T. Lind, Differential effects of polyamine derivative compounds against Leishmania infantum promastigotes and axenic amastigotes. Int J Parasitol.2005; 35 :637–646. [19]. Nasereddin A, Schweynochb C, Schonianb G, Jaffe JL. Characterization of Leishmania (Leishmania) tropica axenic amastigotes. Acta Tropica. 2010;113:72–79.
[20]. Nejad-Moghaddam A, Abolhassani M. Production and characterization of monoclonal antibodies recognizing a common 57-kDa antigen of Leishmaniaspecies. Iran Biomed J. 2009; 13:245-51.

[21]. Justin L , The History of Monoclonal Antibody Development - Progress, Remaining Challenges and Future Innovations. Annals of Medicine and Surgery.2014; 3(4):113-116.

[22]. Froes AM, dos Santos CVD, Penha-Filho ML,Teixeira MCA et al. Sub-clinical infection as an effective protocol for obtaining anti-Leishmania chagasi amastigot antibodies of different animal species. Veterinary Immunol Immunopathol. 2004;99:135–141.

[23]. Chaves C S, Soares, DD, Da Siva R P, Saraiva EM. Characterization of the species-and stage specificity of two monoclonal antibodies against Leishmania amazonensis. Exp Parasitol. 2003; 103:152-159.

[24]. Thaı´s G.V. Silveira1, Erika Suzuki, Helio K.Takahashi, Anita H. Inhibition of macrophage invasion by monoclonal antibodies specific to Leishmania (Viannia) braziliensis promastigote and characterization of their antigens braziliensis. Int. J. Parasitol. 2001;31:1451–1458.

Preparation of Monoclonal Antibodies against proamastigote Leishmania infantum strain in Iran

References

References

Volume 28, Issue 2May and June 2021Pages 302-310

Volume 28, Issue 2
May and June 2021
Pages 302-310